IJPR  articles are Indexed in SCOPUS (2010 - 2021)Click Here     *Five Years Citation in Google scholar (2016 - 2020) is. 1451*        Now IJPR is Q2 in SJR Ranking     Scopus Coverage of IJPR (2010-2021 Issue 1)            

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Humanistic Outcome Assessment of Type 2 Diabetes Mellitus Patients: A Prospective Study

Author: SADAGOBAN G K, S PREETHA, ANGELA ABRAHAM EDAYADI, SWATHI SWAROOPA BORRA, AYILYA M, ARUN KANNIYAPPAN PARTHASARATHY
Abstract: Objectives: Understanding and measuring the patient’s perception on type 2 diabetes mellitus (DM) treatment’s and its related health outcomes are important for developing type 2 DM treatment strategic choices which helps clinicians to make appropriate decisions and benefit the patients. Methods: In this context we conducted a study on type 2 DM patients (n=68) using the translated and validated Diabetes Symptoms Check list -revised (DSC-r) (Tamil Version) Scale for measuring the patient’s perception on type 2 DM treatment options. Selected type 2 DM patients were categorized based on their oral hypoglycemic regimens such as, Metformin with Glipizide (M+ GP), Metformin with Glibenclamide (M+GB) and Metformin (M). DSC-r 34 items self-administering questionnaire was used to measure the type 2 DM patients HRQoL status on 8 major type 2 DM symptom domains such as cardiology, neurology, ophthalmology, psychology, hypoglycemia, hyperglycemia, fatigue, pain. Results: The DSC-r Mean Dimensional Score (MDS) were identified and it was found to be 1.97896 for M +GP treated group, 2.06448 for M+GB treated group and 1.96597 for M treated group. Conclusions: Humanistic outcome analysis results showed that all the three anti-diabetic regimens produced only partial health status with the quality-adjusted life-year (QALY) average of about 0.60/Year.
Keyword: Pharmacoeconomics, Type 2 Diabetes Mellitus, Humanistic Outcome, Health Related Quality of Life, Burden of Disease
DOI: https://doi.org/10.31838/ijpr/2021.13.02.124
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free